Quick Answer
Tempest Therapeutics, Inc. reported Operating Income Loss of -$26.58 million for the year ending 2025.
- Tempest Therapeutics, Inc. showed an increase of +36.8% in Operating Income Loss from 2024 to 2025.
- This data is from Tempest Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: -$410.0 thousand | Q3 2011: -$774.0 thousand | Q2 2012: -$3.23 million | Q3 2012: -$3.12 million | Q1 2013: -$5.18 million | Q2 2013: -$6.02 million | Q3 2013: -$6.93 million | Q1 2014: -$7.65 million | Q2 2014: -$9.60 million | Q3 2014: -$12.40 million | Q1 2015: -$16.81 million | Q2 2015: -$17.17 million | Q3 2015: -$17.77 million | Q1 2016: -$21.44 million | Q2 2016: -$18.24 million | Q3 2016: -$18.96 million | Q1 2017: -$14.59 million | Q2 2017: -$17.93 million | Q3 2017: -$9.41 million | Q1 2018: -$4.39 million | Q2 2018: -$4.99 million | Q3 2018: -$7.81 million | Q1 2019: -$10.66 million | Q2 2019: -$10.16 million | Q3 2019: -$11.75 million | Q1 2020: -$12.14 million | Q2 2020: -$5.24 million | Q3 2020: $5.43 million | Q1 2021: -$5.13 million | Q2 2021: -$6.79 million | Q3 2021: -$7.74 million | Q1 2022: -$8.16 million | Q2 2022: -$8.77 million | Q3 2022: -$8.77 million | Q1 2023: -$7.58 million | Q2 2023: -$7.47 million | Q3 2023: -$6.59 million | Q1 2024: -$7.97 million | Q2 2024: -$9.58 million | Q3 2024: -$10.55 million | Q1 2025: -$10.94 million | Q2 2025: -$7.97 million | Q3 2025: -$3.60 million.
- Over the full 14 years of available data (2012 to 2025), Tempest Therapeutics, Inc.'s Operating Income Loss has declined by 96.4%.
- Historical annual values: Fiscal year 2025: -$26.58 million | Fiscal year 2024: -$42.03 million | Fiscal year 2023: -$29.16 million | Fiscal year 2022: -$34.64 million | Fiscal year 2021: -$26.99 million | Fiscal year 2020: -$19.30 million | Fiscal year 2019: -$45.40 million | Fiscal year 2018: -$26.87 million | Fiscal year 2017: -$84.33 million | Fiscal year 2016: -$81.01 million | Fiscal year 2015: -$72.00 million | Fiscal year 2014: -$47.93 million | Fiscal year 2013: -$29.13 million | Fiscal year 2012: -$13.53 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: